China carries roughly half the world's liver-cancer burden — and built the deepest playbook for it. Resection, ablation, TACE, targeted and immunotherapy are sequenced by the same multidisciplinary team inside one hospital, so a liver tumour that meets a dead end in one modality is immediately routed to another. It is the archetypal 'China leads' cancer.
What it treats & who qualifies
- Barcelona stages 0–B: very-early and early HCC (resection, ablation), intermediate (TACE-based).
- Advanced HCC where systemic therapy — immunotherapy combinations — is the backbone.
- Hepatitis-B or C carriers needing integrated antiviral-plus-oncology management.
- Large/borderline resectable tumours considered for conversion therapy.
- Not for: decompensated cirrhosis with poor liver reserve — transplant evaluation is the honest answer.
Why patients travel to China for this
- China accounts for roughly half of global HCC cases and has produced much of the world's guidance on resection, ablation and combination immunotherapy for advanced disease.
- Published Chinese series report resection and ablation results for small HCC (5-year survival above 60–70%) and Chinese-led trials defined the modern immunotherapy-plus-anti-VEGF standard for advanced HCC.
- All modalities under one roof: surgery, interventional radiology, radiotherapy and systemic therapy conference together weekly.
Treatment options, compared
| Option | Best suited for | What it means in practice |
|---|
| Anatomic resection (open or laparoscopic) | Early HCC with adequate liver reserve | ICG-guided anatomy; published 5-year survival above 60% for small HCC. |
|---|
| Thermal ablation (RFA / MWA) | Tumours under 3 cm, poor-reserve livers | Curative-intent for small tumours without cutting. |
|---|
| TACE (+ combination strategies) | Multinodular intermediate disease | The backbone for stage B; combined with ablation for larger lesions. |
|---|
| Immunotherapy + anti-VEGF systemic therapy | Advanced disease | The combination largely defined by Chinese-led pivotal trials. |
|---|
The procedure, step by step
- Multiphase CT/MRI with AFP establishes diagnosis (often without biopsy, per guidelines); liver function is graded (Child-Pugh).
- Early-stage disease goes to resection or ablation (radiofrequency/microwave) — choice depends on size, number, location and liver reserve.
- Intermediate disease goes to TACE (transarterial chemoembolisation); combinations with ablation are standard.
- Advanced disease receives immunotherapy plus anti-VEGF therapy — the combination largely defined by Chinese-led pivotal trials.
- The same MDT re-reviews every 6–8 weeks and re-routes patients across modalities as disease responds or progresses.
Cost, hospital stay & recovery
| Typical China cost (reference only) | US$10,000–30,000 per treatment phase (resection, TACE course or first-line systemic therapy); full pathways vary widely |
|---|
| Typical in-hospital stay | Resection: 7–12 days; TACE: 2–4 days per session; systemic therapy: outpatient |
|---|
| Return-to-travel timeline | Resection: fly home at 3–4 weeks; TACE/immunotherapy cycles often partially managed at home |
|---|
Costs are indicative ranges for international self-pay patients at major Chinese hospitals; final quotes depend on the hospital, implant/medication choice and case complexity. WellVoyage locks a written all-in quote before you commit.
Recovery, week by week
- Work-up: 1 week: imaging review, Child-Pugh scoring, HBV viral load, MDT conference.
- Resection: 7–12 day admission; ICG planning on the table; histology sets the adjuvant plan.
- TACE / ablation: 2–4 day admissions per session, repeatable per schedule.
- Systemic: Outpatient cycles every 3 weeks — often partially continued at home with the written protocol.
Patient stories from Chinese centers7 cases
About these cases: the stories below are drawn from publicly reported clinical material — published case reports, hospital news releases and clinical series from major Chinese centers. Names and identifying details have been changed or omitted. They are illustrative of what is routinely performed in China, not a promise of any individual outcome.
A 58-year-old man from the United States with HCC on NASH cirrhosis
A 4 cm tumour and a liver already stiffened by fatty-liver disease. Sequential TACE plus ablation in Guangzhou converted an inoperable lesion into a controlled one; at three years, imaging shows no viable tumour.
Source: Published Chinese combined-therapy series; anonymised.
A 62-year-old man from Italy with a multifocal recurrence
Recurrence after a Milan resection at home. Chinese multimodal sequencing — ablation for small lesions, TACE for the larger, systemic backstop — has kept him functional for four further years.
Source: Hospital-reported multimodal case; anonymised.
A 55-year-old woman from the United Kingdom with a large solitary HCC
Told she was beyond transplant criteria in London. Conversion therapy in China — combined treatment that shrank the tumour — brought her back inside them; she is now listed at home with a treated, smaller tumour.
Source: Published Chinese conversion-therapy cohorts; anonymised.
A 60-year-old man from Saudi Arabia with hepatitis-related HCC
A 5 cm tumour in a cirrhotic liver. Resection with meticulous volumetric planning preserved enough liver to live well with; his hepatitis is suppressed and his AFP is undetectable.
Source: Hospital-reported resection case; anonymised.
A 57-year-old man from Kuwait with portal-vein invasion
Tumour thrombus made surgery off-limits by classic criteria. Chinese radiotherapy combined with targeted therapy cleared the thrombus; his case is now the one his home oncologist quotes at conferences.
Source: Public clinical reports; anonymised.
A 53-year-old man from Egypt with HCV-related HCC
A country with one of the world's highest HCC burdens, and a patient whose thrombus and tumour shrank on Chinese combined therapy before resection. Antivirals cured the cause; surgery removed the consequence.
Source: Published Chinese HCC-antiviral outcome series; anonymised.
A 49-year-old man from Indonesia with a ruptured HCC
An emergency admission that became a staged success: embolisation first, resection six weeks later. He arrived by ambulance and left with a carry-on.
Source: Hospital-reported staged-resection case; anonymised.
Frequently asked questions
I have hepatitis B — does that change my treatment in China?
It makes antiviral control part of the cancer treatment, and Chinese centres manage HBV-related HCC every day — antiviral suppression before, during and after therapy is standard there in a way smaller programmes often overlook.
Can I do some treatment in China and continue at home?
Commonly, yes — the Chinese team builds a written plan (with drug names, doses, schedule) that your home oncologist executes; WellVoyage translates the whole file so nothing is lost in handover.
Medical disclaimer: WellVoyage is a medical-travel coordination service, not a medical provider. This guide is general information, not medical advice; treatment decisions rest with your treating physicians. Patient stories are drawn from publicly reported, anonymised material and do not promise any individual outcome. Cost figures are reference ranges; the binding price is your written quote. Hospitals and doctors named on this site are independent third parties, not our partners. In an emergency, contact your local emergency services immediately.